Harmony Biosciences’ FDA setback for pitolisant in idiopathic hypersomnia doesn’t impact its 2025 revenue outlook, with a Phase 3 trial planned for late 2025.
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
Where Today's News Shapes Tomorrow
